Crystalline salt forms of SBT-20
Disclosed are various crystalline salt forms of L-Phe-D-Arg-L-Phe-L-Lys-NH 2 .
1. A crystalline form of a salt of Compound (I),
wherein said crystalline form has characteristic peaks in its x-ray powder diffraction (XRPD) pattern at values of two theta as described in any one of Tables 32-36;
wherein the values of two theta described in Table 32 are:
4.2261
5.0243
6.6588
8.2982
8.6421
10.0369
10.9707
12.3486
16.4828
19.6073
20.1651
24.8069
29.0247
wherein the values of two theta described in Table 33 are:
4.4004
5.4676
6.7036
8.4749
8.9195
11.1651
12.2024
15.6936
16.4475
17.7995
18.5661
19.8016
24.7466
25.663
26.1011
29.1061
wherein the values of two thea described in Table 34 are:
7.2369
10.2443
18.5712
19.9056
20.5017
22.3429
25.8406
26.8697
27.6899
29.5416
wherein the values of two theta described in Table 35 are:
16.3125
17.2726
18.4711
19.0356
20.6684
21.1735
21.6748
22.0235
22.8225
23.4813
24.8323
26.1425
26.9707
28.2387
wherein the values of two theta described in Table 36 are:
4.2472
5.6124
6.005
6.5059
7.3139
8.3849
9.0331
9.3884
10.976
11.6992
12.2816
12.8483
13.6768
14.5232
15.3546
16.434
16.79
17.4904
17.9183
18.5267
19.2386
19.8404
20.5197
20.8647
21.3043
21.7736
22.1003
22.656
23.2875
23.7016
24.3712
24.9261
25.4669
25.7584
26.8617
27.8642
29.0847.
2. A crystalline form of a salt of Compound (I),
wherein said crystalline form has characteristic peaks in its x-ray powder diffraction (XRPD) pattern as described in any one of FIGS. 1-5 .
3. A crystalline form of a lysine salt of Compound (I),
wherein said crystalline form has characteristic peaks in its x-ray powder diffraction (XRPD) pattern at values of two theta (° 2θ) of: 4.2, 8.3, 12.3, 16.5, 24.8, and 29.0.
4. The crystalline form of claim 3 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 4.2, 5.0, 6.6, 8.3, 8.6, 10.0, 11.0, 12.3, 16.5, 19.6, 20.2, 24.8, and 29.0.
5. A crystalline form of a lysine salt of Compound (I),
wherein said crystalline form has characteristic peaks in its x-ray powder diffraction (XRPD) pattern at values of two theta (° 2θ) of: 4.4, 6.7, 8.5, 8.9, 11.2, 15.7, 16.4, 19.8, and 24.7.
6. The crystalline form of claim 5 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 4.4, 5.5, 6.7, 8.5, 8.9, 11.2, 12.2, 15.7, 16.4, 17.8, 18.6, 19.8, 24.7, 25.7, 26.1, and 29.1.
7. A crystalline form of an arginine salt of Compound (I),
wherein said crystalline form has characteristic peaks in its x-ray powder diffraction (XRPD) pattern at values of two theta (° 2θ) of: 7.2, 10.2, 18.6, 19.9, 20.5, 22.3, and 26.9.
8. The crystalline form of claim 7 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 7.2, 10.2, 18.6, 19.9, 20.5, 22.3, 25.8, 26.9, 27.7, and 29.5.
9. A crystalline form of a serine salt of Compound (I),
wherein said crystalline form has characteristic peaks in its x-ray powder diffraction (XRPD) pattern at values of two theta (° 2θ) of: 16.3, 17.3, 19.0, 20.7, 22.8, 23.5, 24.8, and 28.2.
10. The crystalline form of claim 9 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 16.3, 17.3, 18.5, 19.0, 20.7, 21.2, 21.7, 22.0, 22.8, 23.5, 24.8, 26.1, 27.0, and 28.2.
11. A crystalline form of a tosylate salt of Compound (I),
wherein said crystalline form has characteristic peaks in its x-ray powder diffraction (XRPD) pattern at values of two theta (° 2θ) of: 4.2, 5.6, 8.4, 19.2, 19.8, 21.8, 24.4, and 24.9.
12. The crystalline form of claim 11 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 4.2, 5.6, 7.3, 8.4, 9.0, 13.7, 16.4, 16.8, 19.2, 19.8, 21.8, 22.1, 22.7, 24.4, and 24.9.
13. A composition, comprising a crystalline form of claim 1 .
14. A process for making a pharmaceutical composition comprising Compound (I),
comprising dissolving a crystalline form of claim 1 .